SEC Form D raise Raised $108.1M (Form D filed Mar 17, 2026); since then posted 5 roles. SEC Form D 0001231919-26-000259 (Mar 17, 2026)Evidence (1 event)
Mar 17, 2026 · SEC Form D 0001231919-26-000259 Name of Issuer: Strand Therapeutics Inc.; CIK: 1778475; Address: Boston, MA; Submission type: D; Filing date: 2026-03-17; Industry Group: Biotechnology; Date of First Sale: 2025-05-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120099940; Total Amount Sold: 108099927; Federal exemptions: 06b
Board tracked Radar started tracking this company’s job board (8 open jobs at last check). source ↗
Trial start 1: Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab source ↗
Trial start 1: Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab source ↗
Upcoming milestones
2027-05 (ESTIMATED) · 1 · Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab · NCT06249048
Jul 17, 2030 (ESTIMATED) · 1 · Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab · NCT07751042
Estimated primary completion per ClinicalTrials.gov. Dates move.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
1
Recruiting
May 3, 2024
2027-05 (estimated)
NIH awards 3
Annual award amounts. Total $1.2M.
NIH award 1R43CA261487-01 FY2021: $399,508 awarded for that fiscal year; activity R43 (SBIR); PI SOWELL, RYAN; recipient as written: STRAND THERAPEUTICS INC, Cambridge, MA. Development of Programmable mRNA Circuits f source ↗
NIH award 1R43CA250745-01A1 FY2021: $399,725 awarded for that fiscal year; activity R43 (SBIR); PI KITADA, TASUKU; recipient as written: STRAND THERAPEUTICS INC, Cambridge, MA. Engineering a potent locally-acting int source ↗
NIH contract (government contract; not a grant and not an investment round) 75N91021C00027-0-9999-1 FY2021: $399,962 awarded for that fiscal year; activity N43 (OTHER_NIH); PI SIMON, ANNA; recipient as written: STRAND THERAPEUTICS INC, Cambridge, MA. TOPIC 414 source ↗
